Natural compound squalamine may prevent Parkinson’s pathology

A recent study published in Proceedings of The National Academy of Sciences has identified a compound that could be used for the future treatment of Parkinson’s disease (PD). In the preliminary findings, the naturally-occurring compound squalamine was observed to both block α-synuclein aggregation in the brain and suppress the toxicity of these particles. Previously, squalamine and its synthetic analogs have been investigated in clinical trials for its potential uses in treating eye conditions and as an anticancer therapy. In the new study, researchers from the University of Cambridge (UK) and Georgetown University (WA, USA) demonstrated – in both in vivo...